Edgestream Partners L.P. Acquires 14,244 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Edgestream Partners L.P. increased its IDEXX Laboratories stake by 640.2% in the first quarter, purchasing 14,244 additional shares to hold 16,469 shares valued at approximately $9.25 million.
• Institutional investors own 87.84% of IDEXX, with major holders including State Street, J. Stern & Co., Geode Capital Management and Invesco increasing their positions.
• IDEXX exceeded quarterly expectations, reporting $3.47 in EPS and $1.14 billion in revenue, while analysts maintain a “Moderate Buy” consensus and a $749 average price target.

Edgestream Partners L.P. boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 640.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,469 shares of the company's stock after buying an additional 14,244 shares during the quarter. Edgestream Partners L.P.'s holdings in IDEXX Laboratories were worth $9,254,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Elyxium Wealth LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $3,666,459,000. State Street Corp raised its stake in IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock valued at $2,473,817,000 after acquiring an additional 138,956 shares during the period. J. Stern & Co. LLP raised its stake in IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock valued at $1,795,072,000 after acquiring an additional 2,642,200 shares during the period. Geode Capital Management LLC raised its stake in IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock valued at $1,749,380,000 after acquiring an additional 86,263 shares during the period. Finally, Invesco Ltd. lifted its holdings in IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock valued at $1,016,296,000 after purchasing an additional 181,955 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.0%

NASDAQ IDXX opened at $569.46 on Thursday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.92 billion, a price-to-earnings ratio of 41.93, a PEG ratio of 3.12 and a beta of 1.55. The company has a 50 day moving average of $557.25 and a 200-day moving average of $591.71. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 earnings per share. The firm's quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 price objective for the company. UBS Group dropped their price objective on shares of IDEXX Laboratories from $640.00 to $620.00 and set a "neutral" rating on the stock in a research report on Monday. Weiss Ratings cut shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $749.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source